A single intravenous (IV) dose of 3 mg/kg (0.1 mg/kg payload) HER2 ADC led to complete tumor regressions in all mice in an antigen-dependent manner, whereas 5 mg/kg diABZI induced only modest anti-tumor activity despite being administered at a 50-fold higher dose than the ADC payload (Fig. 2a). Here, ERBB2 is linked to neoplasm.